Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - zinc gluconate, quantity: 18.8 mg (equivalent: zinc, qty 2.7 mg) - tablet, chewable - excipient ingredients: isomalt; sorbitol; povidone; microcrystalline cellulose; sucralose; magnesium stearate; stearic acid; colloidal anhydrous silica; flavour - antioxidant/reduce free radicals formed in the body ; maintain/support healthy growth and development ; orexigenic/improve/promote healthy appetite ; maintain/support healthy appetite ; maintain/support immune system health ; helps enhance/improve/promote immune system function ; maintain/support (state vitamin/mineral/nutrient) levels in the body

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - ubidecarenone, quantity: 150 mg - capsule, soft - excipient ingredients: glycerol; gelatin; iron oxide yellow; iron oxide black; soya oil; titanium dioxide; white beeswax; hydrogenated vegetable oil; purified water; iron oxide red; sorbitol solution (70 per cent) (non-crystallising) - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; enhance/promote energy levels ; maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health ; helps enhance/promote blood vessel health ; helps enhance/improve/promote/increase physical/exercise performance

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - ubidecarenone, quantity: 50 mg - capsule, soft - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); gelatin; glycerol; iron oxide black; soya oil; hydrogenated vegetable oil; iron oxide yellow; iron oxide red; titanium dioxide; white beeswax - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; enhance/promote energy levels ; maintain/support energy levels ; maintain/support energy production ; maintain/support general health and wellbeing ; helps in the maintenance of healthy blood lipids/blood fats ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health ; helps enhance/promote blood vessel health ; helps enhance/improve/promote/increase physical/exercise performance

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [see warnings and precautions (5.6)] risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate.  the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc.  parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration (2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions (5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients.  in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

United States - English - NLM (National Library of Medicine)

piramal critical care inc. - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [ see warnings and precautions ( 5.6) ]. risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo-fetal risk deficiency of trace elements, including zinc, is associated with adverse pregnancy and fetal outcomes. pregnant women have an increased metabolic demand for trace elements, including zinc. parenteral nutrition with zinc should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary zinc is present in human milk. administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause harm to a breastfed infant. there is no information on the effects of zinc sulfate on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zinc sulfate injection and any potential adverse effects on the breastfed infant from zinc sulfate injection or from the underlying maternal condition. zinc sulfate injection is approved for use in the pediatric population, including neonates, as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. safety and dosing recommendations in pediatric patients are based on published literature describing controlled studies of zinc-containing products in pediatric patients [see dosage and administration ( 2.2)] . because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with zinc sulfate injection may be at higher risk of aluminum toxicity [see warnings and precautions ( 5.3)] . reported clinical experience with intravenous zinc sulfate has not identified a difference in zinc requirements between elderly and younger patients. in general, dose selection should be individualized based on the patient’s clinical condition, nutritional requirements, and additional nutritional intake provided orally or enterally to the patient.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - zinc acetate (unii: fm5526k07a) (zinc cation - unii:13s1s8sf37) - zinc cation 25 mg - zinc acetate therapy is indicated for maintenance treatment of patients with wilson’s disease who have been initially treated with a chelating agent (see precautions: monitoring patients). zinc acetate capsules are contraindicated in patients with known hypersensitivity to any of the components of the formulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - zinc amino acid chelate, quantity: 25 mg (equivalent: zinc, qty 5 mg); lysine hydrochloride, quantity: 1 g; ascorbic acid, quantity: 200 mg - tablet, uncoated - excipient ingredients: stearic acid; povidone; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; magnesium stearate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support collagen formation ; maintain/support collagen health ; maintain/support immune system health ; helps enhance/improve/promote immune system function ; maintain/support healthy immune system function ; helps reduce occurrence of facial cold sores ; decrease/reduce/relieve burning/tingling associated with facial cold sores ; enhance/improve/promote healing of facial cold sores ; decrease/reduce/relieve symptoms of facial cold sores (linked indication:decrease/reduce/relieve burning/tingling associated with facial cold sores); decrease/reduce/relieve symptoms of facial cold sores ; maintain/support skin health ; enhance/improve/promote skin healing ; maintain/support wound healing ; enhance/improve/promote skin repair/healing

Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc.; importer: n/a; distributor: tgp pharma, inc. - tgp zinc gluconate - syrup (orange flavor) - 10 mg (equivalent to 70 mg zinc gluconate)/5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

nature's care manufacture pty limited - calcium ascorbate, quantity: 60.52 mg (equivalent: ascorbic acid, qty 50 mg); ferrous fumarate, quantity: 16.01 mg (equivalent: iron, qty 5 mg); biotin, quantity: 2.6 mg; zinc gluconate, quantity: 195.3 mg (equivalent: zinc, qty 25 mg); silicon dioxide, quantity: 86.56 mg (equivalent: silicon, qty 40 mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; purified water; gelatin; sodium lauryl sulfate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; helps enhance/promote collagen formation ; maintain/support collagen formation ; maintain/support collagen health ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support hair growth ; enhance/improve/promote/increase hair growth ; maintain/support hair health ; enhance/improve/promote/increase hair health ; enhance/improve/promote/increase hair strength/thickness ; maintain/support hair strength/thickness ; decrease/reduce nail brittleness/splitting/chipping ; aid/assist nail growth ; maintain/support nail health/strength/thickness ; enhance/improve/promote/increase nail health/strength/thickness ; maintain/support immune system health ; maintain/support healthy immune system function ; helps enhance/promote skin health ; maintain/support skin health ; maintain/support skin integrity/structure ;

European Union - English - EMA (European Medicines Agency)

3m health care limited - rivastigmine - alzheimer disease - psychoanaleptics, , anticholinesterases - symptomatic treatment of mild to moderately severe alzheimer's dementia.